Meloxicam (Mobic)Nonsteroidal anti-inflammatory drug CAS# 71125-38-7 |
- FK 3311
Catalog No.:BCC1576
CAS No.:116686-15-8
- Iguratimod
Catalog No.:BCC1641
CAS No.:123663-49-0
- Celecoxib
Catalog No.:BCC1099
CAS No.:169590-42-5
- Etoricoxib
Catalog No.:BCC1565
CAS No.:202409-33-4
- Ibuprofen Lysine
Catalog No.:BCC2547
CAS No.:57469-77-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 71125-38-7 | SDF | Download SDF |
| PubChem ID | 54677470 | Appearance | Powder |
| Formula | C14H13N3O4S2 | M.Wt | 351.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (142.29 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide | ||
| SMILES | CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O | ||
| Standard InChIKey | ZRVUJXDFFKFLMG-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Meloxicam is a nonsteroidal anti-inflammatory agent with analgesic and fever reducer effects.
Target: COX-2
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis, primary dysmenorrhea, fever; and as an analgesic, especially where there is an inflammatory component. It is closely related to piroxicam. In Europe it is marketed under the brand names Movalis, Melox, and Recoxa. In North America it is generally marketed under the brand name Mobic. In Latin America, the drug is marketed as Tenaron. The pregnancy rate with meloxicam administration using the emergency contraception model was 6.5%, significantly lower than the pregnancy rate of 33.3% when vehicle without meloxicam was administered. Pregnancy rates with the three monthly contraceptive models (75%-100%) were not consistent with preventing pregnancy [1]. OA rats receiving intra-articular meloxicam treatment showed significantly less cartilage degeneration and synovitis than saline-treated controls. Nociception were improved in the OA + meloxicam groups compared with the OA group. Moreover, meloxicam attenuated p38 and JNK but enhanced ERK expression in OA-affected cartilage [2]. References: | |||||
Meloxicam (Mobic) Dilution Calculator
Meloxicam (Mobic) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8458 mL | 14.2288 mL | 28.4576 mL | 56.9152 mL | 71.144 mL |
| 5 mM | 0.5692 mL | 2.8458 mL | 5.6915 mL | 11.383 mL | 14.2288 mL |
| 10 mM | 0.2846 mL | 1.4229 mL | 2.8458 mL | 5.6915 mL | 7.1144 mL |
| 50 mM | 0.0569 mL | 0.2846 mL | 0.5692 mL | 1.1383 mL | 1.4229 mL |
| 100 mM | 0.0285 mL | 0.1423 mL | 0.2846 mL | 0.5692 mL | 0.7114 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis (juvenile rheumatoid arthritis, osteoarthritis, and rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure arthritis and will only help you as long as you continue to take it.
- Bucindolol
Catalog No.:BCC7444
CAS No.:71119-11-4
- MRS 2578
Catalog No.:BCC4976
CAS No.:711019-86-2
- 5,8,4'-Trihydroxy-7-methoxyflavone 8-O-glucoside
Catalog No.:BCN1372
CAS No.:710952-13-9
- Griselinoside
Catalog No.:BCN4272
CAS No.:71035-06-8
- 1-Octacosanoyl glyceride
Catalog No.:BCN8190
CAS No.:71035-02-4
- Cathinone
Catalog No.:BCN1784
CAS No.:71031-15-7
- Digitoxin
Catalog No.:BCN5358
CAS No.:71-63-6
- Veratridine
Catalog No.:BCC7515
CAS No.:71-62-5
- Medroxyprogesterone acetate
Catalog No.:BCC4485
CAS No.:71-58-9
- butanol
Catalog No.:BCN4976
CAS No.:71-36-3
- Cytosine
Catalog No.:BCN8533
CAS No.:71-30-7
- H-His-OH
Catalog No.:BCC2954
CAS No.:71-00-1
- (E)-3-Acetoxy-5-methoxystilbene
Catalog No.:BCN4273
CAS No.:71144-78-0
- (±)-Bay K 8644
Catalog No.:BCC3918
CAS No.:71145-03-4
- Leukotriene B4
Catalog No.:BCC7322
CAS No.:71160-24-2
- ML 141
Catalog No.:BCC8092
CAS No.:71203-35-5
- Erythroxytriol P
Catalog No.:BCN4274
CAS No.:7121-99-5
- Schizandriside
Catalog No.:BCN6999
CAS No.:71222-06-5
- Obolactone
Catalog No.:BCN7190
CAS No.:712272-88-3
- Boc-Ala(2-pyridyl)-OH
Catalog No.:BCC3320
CAS No.:71239-85-5
- Salaspermic acid
Catalog No.:BCN7139
CAS No.:71247-78-4
- 2,5-Bis(5-tert-butyl-2-benzoxazolyl)thiophene
Catalog No.:BCC8503
CAS No.:7128-64-5
- Crotananine
Catalog No.:BCN2078
CAS No.:71295-28-8
- Cronaburmine
Catalog No.:BCN2072
CAS No.:71295-32-4
[Meloxicam (Mobic): a review of its pharmacological and clinical profile].[Pubmed:12528470]
Nihon Yakurigaku Zasshi. 2002 Dec;120(6):391-7.
Meloxicam (Mobic) is a new nonsteroidal anti-inflammatory drug (NSAID) derived from enolic acid, exhibiting selectivity for cyclooxygenase (COX)-2 over COX-1. Meloxicam has shown potent anti-inflammatory and analgesic activity together with low gastrointestinal toxicity in animal models. It is a potent inhibitor not only of acute exudation in adjuvant arthritis in the rat, but also of bone and cartilage destruction. The therapeutic range of meloxicam in the rat, with regard to inhibition of adjuvant arthritis, was several times greater than that of other NSAIDs. Meloxicam in therapeutic doses was found to have no effect on bleeding time or platelet aggregation in healthy volunteers. In clinical studies, meloxicam has shown reliable efficacy against rheumatoid arthritis, osteoarthritis, lumbago (low back pain), scapulohumeral periarthritis, and neck-shoulder-arm syndrome with low gastrointestinal toxicity.
Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats.[Pubmed:24084190]
Osteoarthritis Cartilage. 2013 Dec;21(12):1976-86.
OBJECTIVE: To study the effect of intra-articular injection of Meloxicam (Mobic) on the development of osteoarthritis (OA) in rats and examine concomitant changes in nociceptive behavior and the expression of mitogen-activated protein kinases (MAPKs) in articular cartilage chondrocytes. METHODS: OA was induced in Wistar rats by right anterior cruciate ligament transection (ACLT); the left knee was not treated. The OA + meloxicam (1.0 mg) group was injected intra-articularly in the ACLT knee with 1.0 mg of meloxicam once a week for 5 consecutive weeks starting 5 weeks after ACLT. The OA + meloxicam (0.25 mg) group was treated similarly with 0.25 mg meloxicam. The sham group underwent arthrotomy only and received vehicle of 0.1 mL sterile 0.9% saline injections, whereas the naive rats in meloxicam-only groups were treated similarly with 1.0- and 0.25-mg meloxicam. Nociception was measured as secondary mechanical allodynia and hind paw weight-bearing distribution at before (pre-) and 5, 10, 15, and 20 weeks post-ACLT. Histopathology of the cartilage and synovia was examined 20 weeks after ACLT. Immunohistochemical analysis was performed to examine the effect of meloxicam on MAPKs (p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK)) expression in the articular cartilage chondrocytes. RESULTS: OA rats receiving intra-articular meloxicam treatment showed significantly less cartilage degeneration and synovitis than saline-treated controls. Nociception were improved in the OA + meloxicam groups compared with the OA group. Moreover, meloxicam attenuated p38 and JNK but enhanced ERK expression in OA-affected cartilage. CONCLUSIONS: Intra-articular injection of meloxicam (1) attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly through inhibition of cellular p38 and JNK, but enhances ERK expression.
